MilliporeSigma Collaborates with Baylor College of Medicine to Develop COVID-19 Vaccine Candidates.
M2 PHARMA-May 27, 2020-MilliporeSigma Collaborates with Baylor College of Medicine to Develop COVID-19 Vaccine Candidates
(C)2020 M2 COMMUNICATIONS
MilliporeSigma and Baylor College of Medicine have extended their collaboration to focus on process development and improvements to advance vaccine manufacturing to fight COVID-19, the company said.
MilliporeSigma, along with researchers at Baylor College of Medicine and the Texas Children's Hospital Center for Vaccine Development, is optimising the production process to advance two Covid-19 vaccine candidates.
MilliporeSigma will help to accelerate their suitability for large-scale manufacturing. This collaboration will focus on improvements to production efficiency, yield, robustness, scalability and costs.
The MilliporeSigma-Baylor teams will improve the manufacturing platform for the CoV RBD219-N1 vaccine candidate, which was originally developed to target SARS in 2011-2016.
Additionally, they will develop a new manufacturing platform for a second Covid-19 vaccine candidate to shorten the time to enter into Phase 1 clinical trials.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||May 27, 2020|
|Previous Article:||MiraDx Offers COVID-19 PCR Testing for California Skilled Nursing Facilities.|
|Next Article:||Quest Diagnostics Introduces COVID-19 Diagnostic and Antibody Testing for Workplaces.|